Kezar Life Sciences Inc expected to post a loss of 30  cents a share - Earnings Preview

Kezar Life Sciences

08/03/2022 24:20

* Kezar Life Sciences Inc  KZR.OQ   KZR.O  is expected
to show no
change in quarterly revenue when it reports  results on March 9
(estimated). 
    * ​Refinitiv's mean analyst estimate for Kezar Life Sciences
Inc
is for a loss of 30 cents per share. For the same quarter last
year, the company reported a loss of 22 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $20​, about 33% above​ its last closing price
of $13.41. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.26       -0.26      -0.28     Missed  -6.3
 Jun. 30 2021  -0.27       -0.26      -0.25     Beat    3.8
 Mar. 31 2021  -0.24       -0.24      -0.25     Missed  -5.9​
 Dec. 31 2020  -0.25       -0.23      -0.22     Beat    4.5
 ​​Sep.        -0.21       -0.21      -0.23     Missed  -10.6
 30 2020                                                
 Jun. 30 2020  -0.26       -0.26      -0.22     Beat    16.7​
 Mar. 31 2020  -0.36       -0.37      -0.30     Beat    19.9
 Dec. 31 2019              -0.54      -0.50     Beat    7.7
 This summary was machine generated March 8 at 00:20 GMT.  All
figures in US dollars  unless otherwise stated